Literature DB >> 8262888

A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.

J M Jonas1, M S Cohon.   

Abstract

A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant medications). In all, a total of 8878 patients participated in the 84 active-drug-controlled studies that were reviewed: 3574 were treated with alprazolam, 3666 were treated with another active drug, and 1638 were treated with placebo. Two general findings emerged: (1) Alprazolam demonstrates efficacy for the treatment of anxiety disorders, panic disorder, and depression in the large majority of studies; for these illnesses, it appeared equal in efficacy to the active agents with which it was compared. (2) Medical events, such as depression, suicidality, hostility/aggression, mania/psychosis, abuse, withdrawal reactions, and seizures, were reported infrequently or not at all for alprazolam and the comparator drugs; there were no marked differences between drug classes in the frequencies of these events.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262888

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Alprazolam as a monotherapy for anxiety and depression.

Authors:  Tanvir Singh; Muhammad I Rajput
Journal:  Psychiatry (Edgmont)       Date:  2005-11

2.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

3.  Are benzodiazepines antidepressants?

Authors:  G Laakmann; M Faltermaier-Temizel; S Bossert-Zaudig; T Baghai
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

Review 4.  A Review of Alprazolam Use, Misuse, and Withdrawal.

Authors:  Nassima Ait-Daoud; Allan Scott Hamby; Sana Sharma; Derek Blevins
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

Review 5.  Measuring quality of life in patients with depression or anxiety.

Authors:  D Whalley; S P McKenna
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

Review 6.  Alprazolam for depression.

Authors:  Harm van Marwijk; Gideon Allick; Froukje Wegman; Arjan Bax; Ingrid I Riphagen
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 7.  Alprazolam is relatively more toxic than other benzodiazepines in overdose.

Authors:  Geoffrey K Isbister; Luke O'Regan; David Sibbritt; Ian M Whyte
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

8.  Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo.

Authors:  G Laakman; M Faltermaier-Temizel; S Bossert-Zaudig; T Baghai; G Lorkowski
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 9.  Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-11-24       Impact factor: 3.022

10.  Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease.

Authors:  Patrick N Pallier; Elizabeth S Maywood; Zhiguang Zheng; Johanna E Chesham; Alexei N Inyushkin; Richard Dyball; Michael H Hastings; A Jennifer Morton
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.